Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > Recent News
View:
Post by SkywalkerofLuke on May 08, 2023 4:42pm

Recent News

AGN.c AGNPF is working to be a leader in the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe.


They’ve had some good news over the past couple months advancing different drug studies.


Highlights 


- Completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT) for stroke and have been approved to move forward

- Received a Notice of Allowance from the US Patent and Trademark Office for patent application for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast)


The stroke treatment market is est. to reach value of $15B by 2027 and more than 1 in 7 (15% of US adults) are estimated to have chronic kidney disease, some large market applications for these two drugs.


https://www.algernonpharmaceuticals.com/news-media/news-releases

Be the first to comment on this post
Algernon Pharmaceuticals Inc.